Get the Stockscreener App
147.64
1.46%
-2.19
After Hours:
147.50
-0.14
-0.09%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $147.64, with a volume of 8.14M.
It is down -1.46% in the last 24 hours and up +8.61% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$149.83
Open:
$149.72
24h Volume:
8.14M
Relative Volume:
1.12
Market Cap:
$183.17B
Revenue:
$29.42B
Net Income/Loss:
$8.51B
P/E Ratio:
21.78
EPS:
6.7801
Net Cash Flow:
$10.02B
1W Performance:
-4.91%
1M Performance:
+8.61%
6M Performance:
+28.64%
1Y Performance:
+32.97%
1-Day Range:
$147.05
$150.08
1-Week Range:
$147.05
$156.01
52-Week Range:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
147.64 | 185.89B | 29.42B | 8.51B | 10.02B | 6.7801 |
|
LLY
Lilly Eli Co
|
1,042.15 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.28 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.44 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
206.61 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.11 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
GILEAD SCIENCES, INC. SEC 10-K Report - TradingView
Arcellx Stock Explodes 77% After Gilead’s $7.8 Billion Takeover Announcement. Here’s What Investors Should Know - TIKR.com
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel - TradingView
Gilead’s Arcellx Deal Deepens Oncology Focus And Raises Valuation Questions - simplywall.st
Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next - TechStock²
Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says - marketscreener.com
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - BioWorld MedTech
Truist reiterates Gilead Sciences stock rating on Arcellx deal - Investing.com UK
GILD touches the ceiling: Gilead Sciences pulls back after tagging upper channel resistance - FXStreet
Gilead's $7.8 Billion Bet on Arcellx: A New Era for Multiple Myeloma Therapy Begins - Investing News Network
Gilead adds to cell therapy portfolio with $8bn acquisition of Arcellx - European Pharmaceutical Review
Gilead Sciences, Inc. $GILD Shares Bought by Nkcfo LLC - MarketBeat
Pharma Pulse: Eli Lilly’s Multi-Dose Breakthrough and Gilead’s $7.8 Billion Oncology Bet - Pharmaceutical Commerce
Gilead acquires US biotech company for nearly USD 8bn - medwatch.com
AXQ Capital LP Buys Shares of 13,757 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Price Target Increased by 11.73% to 159.01 - Nasdaq
UBS downgrades Arcellx stock rating to neutral on Gilead acquisition - Investing.com
Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx - The Daily Upside
Gilead to buy Arcellx in nearly $8B deal - statnews.com
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Gilead’s Arcellx buy. Plus: ctDNA as surrogate endpoint — a BioCentury podcast - biocentury.com
Gilead brings Arcellx fully under the fold for $7.8B - BioWorld MedTech
Gilead’s Bictegravir/Lenacapavir Noninferiority Data Will Support Switching From Biktarvy - Citeline News & Insights
Why Gilead plans to buy a Bay Area company for $7.8 billion - The Business Journals
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - AOL.com
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J - Investor's Business Daily
Gilead Sciences to Present at Upcoming Investor Conferences - The Joplin Globe
This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. - Barron's
Gilead Raises $7.8 Billion To Acquire Arcellx And Expand Cancer Pipeline - Ventureburn
Evercore ISI cuts Arcellx stock rating to In Line on Gilead acquisition - Investing.com
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer PipelineGEN - GEN - Genetic Engineering and Biotechnology News
Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal - MedCity News
Gilead to Acquire Arcellx in $7.8B Biotech Bet on Cancer Therapy - USA Herald
Morgan Stanley reiterates Overweight on Gilead stock after Arcellx deal - Investing.com
Gilead buying homegrown cancer therapy company Arcellx for $7.8B - The Business Journals
Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition (NASDAQ:GILD) - Seeking Alpha
Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy - Law360
An $8 bln pharma deal prices patent fears - Breakingviews
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition - GuruFocus
This biotech stock is surging 78%. Gilead Sciences agrees to buy it. - MSN
Gilead Sciences Strengthens Oncology Pipeline with Major Acquisition - AD HOC NEWS
Gilead Sciences (GILD) Valuation Check After Strong 3 Month And 1 Year Shareholder Returns - simplywall.st
Arcellx Stock (ACLX) Rockets on a Massive Deal with Gilead Sciences (GILD) - TipRanks
Needham Reiterates Buy Rating for Gilead Sciences (GILD) with $1 - GuruFocus
What Gilead Is Getting Through The Acquisition Of Arcellx - Seeking Alpha
Gilead to acquire CAR-T biotech Arcellx for $7.8bn - European Medical Journal
Gilead to buy Arcellx in $7.8bn deal to advance multiple myeloma treatment - BioXconomy
Gilead Sciences (NASDAQ:GILD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion - marketscreener.com
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive
Arcellx shares surge after Gilead announces $7.8B takeover deal - MSN
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Feb 17 '26 |
Sale |
154.44 |
28,000 |
4,324,228 |
120,288 |
| Dickinson Andrew D | Chief Financial Officer |
Feb 17 '26 |
Sale |
154.43 |
3,000 |
463,290 |
167,779 |
2.62%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):